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1 
1. ABSTRACT 
The effects of felodipine (2.5-5.0 mg po BID) versus placebo were 
evaluated in fourteen patients with concomitant coronary artery disease 
and congestive heart failure already receiving stable doses of enalapril, 
furosemide, and digoxin in a ten-week, prospective, double-blind, 
randomized trial. Felodipine, a dihydropyridine calcium channel 
antagonist, has been found to possess potent peripheral and coronary 
vasodilatory action without a significant negative inotropic effect in 
numerous in vivo and in vitro studies. However, long term use of 
felodipine as add-on therapy to CHF patients already receiving maximal 
medical therapy has not yet been examined. 
Baseline thallium-201 scintigraphy performed on all subjects prior to 
randomization revealed a 58% incidence of clinically and 
electrocardiographically silent myocardial ischemia. Furthermore, the 
addition of felodipine was found to reduce the normalized area of ischemic 
myocardium (-29.0% +/- 9.5, p<.05) in subjects with initial thallium scans 
revealing greater than 10% reversible perfusion defects. Persistent 
afterload reduction was also noted following eight weeks of felodipine 
therapy versus placebo with decreases in mean systolic blood pressure 
(-19.7 mm Hg +/- 8.3, p<.01) and diastolic blood pressure (-5.4 mm Hg +/- 
6.5, p<.05). Given the statistical constraints imposed by the relatively 
small sample size, no associated benefit in terms of either exercise 
tolerance, functional status, or quality of life assessment was found. 
Future studies documenting the clinical efficacy of felodipine in 
coronary patients limited by symptoms of CHF and having scintigraphic 
evidence of 10% or greater reversible myocardial ischemia are warranted. 
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2. INTRODUCTION 
The prevalence of chronic congestive heart failure (CHF) is increasing with more 
than two million people in the United States alone afflicted by this syndrome which 
carries an associated high rate of mortality and morbidity (1). In the United States, 
coronary artery disease is the most common etiology, apparently due to an overall 
decline in the death rate from ischemic heart disease and a subsequent increase in the 
number of coronary patients surviving with poor left ventricular function. Patients 
experiencing symptoms of CHF are commonly encountered both inside the private 
offices of internists and cardiologists as well as occupying an ever greater portion of 
hospital inpatient beds nationwide. 
Although clearly effective as antihypertensive and antianginal agents, the role of 
calcium channel antagonists in the treatment of symptomatic congestive heart failure 
has yet to be determined. Because the majority of patients with CHF have it on the 
basis of ischemic heart disease, anti-ischemic therapy is rational and, yet, has not been 
found to be of significant benefit as presently utilized. Delineation of a treatment 
program designed to maximize hemodynamics while minimizing ischemia could be 
beneficial to a large segment of the CHF population. Felodipine, a calcium channel 
antagonist with an apparent lack of negative inotropic effect, would appear to be an 
ideal drug for this purpose. 
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3. EPIDEMIOLOGY OF CONGESTIVE HEART FAILURE 
Despite the recent decline in overall cardiovascular mortality, the prevalence of 
CHF nationwide has continued to increase with the majority of new cases of ventricular 
dysfunction being due to coronary artery disease (2). It is estimated that about 3 million 
Americans have CHF, representing approximately 1% of the population (3). Given 
recent growth in the geriatric population and the increased incidence of CHF with age, 
the magnitude of this problem can be expected to increase over the next several 
decades. Currently, about 400,000 new cases of CHF are diagnosed every year in the 
United States with the number of hospitalizations partly or wholly due to this condition 
nearly doubling over the last ten years (4). CHF is now the most common hospital 
discharge diagnosis for those over the age of 65. 
The current prognosis with CHF is poor as approximately 200,000 patients die 
from complications each year. The status of left ventricular function has been found to 
be the single best predictor of mortality in most subgroups of patients with coronary 
artery disease. Those patients in whom ventricular dysfunction coexists with 
asymptomatic or "silent" ischemia constitute the highest risk group (5). Data from the 
Framingham study demonstrated a two year mortality rate of 31% and a four year 
mortality rate of 52% among patients with congestive failure (6). Individuals with New 
York Heart Association class IV symptoms have nearly a 50% risk of death within only 
one year (4). Despite improvements in survival with the addition of vasodilators to the 
treatment of CHF, prognosis remains formidible with currently reported one-year and 
three-year mortality rates equaling 25% and 65%, respectively (7). To cast these 
mortality rates in perspective, survival at one and three years following a diagnosis of 
metastatic squamous cell carcinoma of the lung nearly approximates that of patients 
with CHF (8). 

4. PATHOPHYSIOLOGY OF ISCHEMIC CARDIOMYOPATHY AND 
CONGESTIVE HEART FAILURE 
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Insight into the pathophysiology of ischemic cardiomyopathy and congestive 
heart failure provides the rationale for designing an effective and safe medical regimen 
for use in this patient population. 
A. Ischemic Cardiomyopathy 
The pathogenesis of left ventricular dysfunction in patients with coronary artery 
disease is thought by many to be multifactorial. In addition to irreversible areas of 
infarction and myocardial necrosis, reversible or active ischemia, "stunned 
myocardium," and "hibernating myocardium" may contribute variably to the overall 
systolic and diastolic dysfunction observed. Stunned myocardium refers to a reversible 
condition in which an ischemic segment of myocardium displays persistent impairment 
of contractility and diastolic relaxation for up to several days following restoration of 
normal blood flow. Hibernating myocardium is another reversible condition in which 
"myocardial perfusion is chronically reduced, but is still sufficient to maintain the 
viability of the tissue...Myocardial function may remain impaired permanently or for as 
long as myocardial perfusion is inadequate" (12). 
In turn, the clinical spectrum of what has been termed "ischemic cardiomyopathy" 
is also varied. Patients may merely exhibit asymptomatic left ventricular dysfunction 
although symptomatic angina pectoris is frequently noted. Those patients who exhibit 
asymptomatic, or "silent," ischemia may do so spontaneously or exclusively following 
periods of stress and/or activity. It remains unknown to what extent such patients with 
evidence for silent myocardial ischemia exhibit left ventricular dysfunction though 
others have speculated that perhaps "repeated episodes of silent ischemia, though 
brief, or silent infarction, though small, may result in congestive ischemic 
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cardiomyopathy.” (13). Indeed, in one small series of patients with severe painless 
ischemia, there is evidence for such a progression from silent myocardial ischemia to 
marked left ventricular dysfunction and pulmonary edema (14). Survival among 
patients with this syndrome, as in other types of cardiomyopathies, is directly related to 
the degree of left ventricular dysfunction (15), while constituting the subgroup of CHF 
patients at greatest risk for terminal events (5). 
B. Congestive Heart Failure 
Congestive heart failure (left-sided) can be broadly defined as a clinical 
syndrome in which the heart is unable to pump sufficient amounts of blood from the 
pulmonary vasculature to the systemic circulation so as to meet the metabolic needs of 
peripheral tissues, resulting in a symptom complex composed of dyspnea, generalized 
fatigue, and a reduction in exercise tolerance. However, absolute reduction in cardiac 
output as a sole criterion for the definition of CHF has limitations. Rather, the cardiac 
output, metabolic requirements, and left ventricular filling pressures all play essential 
roles in the clinical presentation of CHF. 
The potential causes of congestive heart failure are extremely varied (Table 1). In 
essence, any process that leads to inadequate cardiac output, greater metabolic 
demand, and/or increasing filling pressures may culminate in the clinical symptom 
complex of CHF. In current series in the United States, it appears that in about 50 to 
75% of patients with heart failure, coronary artery disease is the underlying cause (7). 
Other etiologies include increased work load due to hypertension or valvular heart 
disease, abnormal anatomy, altered cardiac rhythm or conduction, and "high output 
states" such as those associated with fever, sepsis, hyperthyroidism, and cocaine and 
amphetamine abuse. Diastolic dysfunction is also being recognized increasingly as a 
cause of CHF with the left ventricle failing to relax sufficiently to permit diastolic filling at 
normal pressures. 
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TABLE 1: Causes of Congestive Heart Failure 
Mechanical Abnormalities Myocardial Abnormalities 
a. Increased pressure load a. Primary 
i. Cardiomyopathy 
ii. Neuromuscular disorders 
iii. Myocarditis 
iv. Metabolic (diabetes, etc.) 
v. Toxic (alcohol, cobalt, etc.) 
vi. Presbycardia 
i. Central (aortic stenosis, etc.) 
ii. Peripheral (systemic hypertension, etc.) 
b. Increased volume load (valvular regurgitation, etc.) 
c. Obstruction to ventricular filling (mitral or tricuspid stenosis) 
d. Pericardial constriction, tamponade 
e. Endocardial or myocardial restriction 
f. Ventricular aneurysm 
g. Ventricular dyssynergy 
b. Secondary 
i. Ischemia 
ii. Dysdynamic disorders 
iii. Metabolic disorders 
iv. Inflammation 
v. Infiltrative diseases 
vi. Systemic disease 
vii. COPD 
viii. Depression (due to drugs) 
Altered Cardiac Rhythm or Conduction Sequence 
a. Standstill 
b. Fibrillation 
c. Extreme tachycardia or bradycardia 
d. Electrical asynchrony, conduction disturbances 
Adapted from Hurst JW, et al. The Heart, 6th edition. New York: McGraw-Hill Book Company (1986), p. 320. 
Progressive weakening of the left ventricle with an attendant decrease in cardiac 
output is manifested by rises in left ventricular end-diastolic pressure, left atrial 
pressure, pulmonary venous pressure, and, finally, pressures within the pulmonary 
capillary bed. The elevated pulmonary pressures, in turn, lead to interstitial edema and 
alveolar edema with accumulations of fluid in the air spaces of the lungs, subjective 
difficulty in breathing, and, ultimately, hypoxia and hypercapnia. The pathophysiology 
of CHF can best be understood by dividing the determinants of cardiac function into 
three aspects: preload, contractility, and afterload. It is the interaction between the left 
ventricle and its loading conditions (preload and afterload) which determines the full 
expression of the congestive heart failure state. 
Physiologically, preload refers to the degree of myocardial fiber stretch at the 
conclusion of diastole. Clinically, preload refers to the volume of blood residing within 
the ventricles just prior to the advent of systole and ejection. The Frank-Starling law 
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relating ventricular function to preload states that as the end-diastolic fiber stretch or 
volume increases, greater stroke volume and, hence, cardiac output will result (Figure 
1). However, since it is difficult to measure either individual cardiac muscle fiber length 
or dynamic changes in ventricular volume, left ventricular end-diastolic pressure is 
used as an indirect measurement of preload, assuming constant compliance. During 
heart failure the Frank-Starling relationship is altered such that greater left ventricular 
filling pressures become required to compensate for the primary myocardial insult and 
produce the original stroke volume (Figure 1). Such compensatory states may 
subsequently develop into "vicious cycles" in which continued increases in left 
ventricular volumes and pressures ultimately lead to further ventricular dysfunction and 
worsening pulmonary and systemic venous congestion. 
FIGURE 1: Frank-Starling Relationship in Normal Heart vs. Failing Heart 
Left ventricular end-diastolic volume 

8 
A fundamental problem for patients with systolic dysfunction is a decline in 
myocardial contractility. Contractility refers to the mechanical performance of the heart 
and the ability of cardiac myofilaments to overlap and shorten against a load. In 
patients with ischemic heart disease, loss of muscle due to myocardial infarction 
imposes an additional volume and wall stress load on the remaining normal 
myocardium. These changes lead to remodeling of the ventricle over time, with fibrosis 
in regions of infarct and hypertrophy of the surrounding intact myocardium. Eventually, 
the hypertrophied tissue may exhibit an intrinsic decrease in contractility and contract 
abnormally, leading to further decline in overall cardiac function (16). An overall 
reduction in myocardial contractility is manifested by a decrease in force and velocity of 
shortening at given loading conditions. These preload and afterload-dependent indices 
of contractility are reflected in a decline in left ventricular ejection fraction and stroke 
volume and an attendant increase in left atrial pressure. 
Afterload represents the sum resistance which the ventricle must overcome in 
order to expel blood from the filled heart, including the amount of left ventricular wall 
stress that must be developed, resistance across the aortic valve, and elasticity of the 
aorta and immediate branching great vessels. Unlike the normal left ventricle, which is 
relatively sensitive to changes in preload and insensitive to changes in afterload, the 
failing left ventricle has the opposite characteristics and is exquisitely 
afterload-sensitive (Figure 2). Assuming there is no aortic stenosis, a reasonable, 
indirect measure of afterload is systemic vascular resistance. Consequently, relatively 
small increases in systemic vascular resistance may significantly reduce stroke volume 
in CHF patients in whom a fragile compensatory balance exists between left ventricular 
preload, afterload and contractility. 
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FIGURE 2: Stroke Volume (SV) Response of 
Normal (NL) & Failing Heart (HF) to Changes in Afterload 
In addition to the hemodynamic derangements primarily due to the failing left 
ventricle, a number of peripheral neurohumoral mechanisms become activated which, 
although initially compensatory, over the long term accentuate the disease state while 
indirectly worsening left ventricular function and pulmonary congestion (Table 2). 
Initially, there is a marked increase in circulating catecholamines and sympathetic tone 
resulting from stimulation of baroreceptors and chemoreceptors as the body attempts to 
preserve cardiac output and blood pressure. Arteriolar vasoconstriction and increased 
systemic vascular resistance result as well as venoconstriction, creating increases in 
both left ventricular filling pressure and venous return. In addition, the increased heart 
rate and contractility not only increase myocardial oxygen demand, but also, by 
reducing diastolic relaxation time, reduce coronary blood flow to the myocardium and 
further contribute to an imbalance between myocardial oxygen supply and demand. 
Finally, prolonged sympathetic stimulation leads to a "down regulation" of beta-1 

receptors residing within the failing myocardium, creating an intrinsic desensitization to 
circulating catecholamines. In severely failing human hearts removed at the time of 
cardiac transplantation, beta-adrenergic receptor density has indeed been observed to 
be reduced by approximately 50% (17). Thus, the abnormal ventricle in congestive 
failure not only is unable to provide a sufficient cardiac output under normal conditions, 
but is also incapable of responding to inotropic stimulation during periods of increased 
demand, further limiting the ability of the heart to meet the needs of the peripheral 
circulation. 
TABLE 2: Neurohormonal and Peripheral Changes in 
Congestive Heart Failure 
Neurohormonal Changes 
a. Increased plasma catecholamines 
b. Activation of renin-angiotensin-aldosterone system 
c. Increased arginine vasopressin (antidiuretic hormone) 
d. Increased atrial natriuretic factor 
Peripheral Changes 
a. Increased systemic vascular resistance 
b. Blunting of baroreceptor reflexes 
c. Decreased vasodilatory response of peripheral vasculature 
d. Altered regional flows 
e. Venoconstriction 
Adapted from Parmley, WW. Pathophysiology and Current Therapy of Congestive Heart Failure. 
J Am Coll Cardiol 13: 774, 1989. 
Reduction in effective renal blood flow, coupled with increased sympathetic 
stimulation, leads to activation of the renin-angiotensin-aldosterone system. 
Angiotensin II has three effects which, over time, may become deleterious to CHF 
patients. First, it is a potent vasoconstrictor that may contribute to excess systemic 
vascular resistance. Second, it tends to facilitate sympathetic outflow that may 
contribute to the already elevated levels of plasma catecholamines. Third, it feeds back 
on the adrenal gland to release aldosterone and thus stimulates renal tubular sodium 

reabsorption, increases salt and water retention, and contributes to the edema-forming 
state seen in patients with heart failure. 
Arginine-vasopressin (antidiuretic hormone) and atrial natriuretic factor have also 
been found to be increased in patients with CHF (18,19) although it is not clear to what 
extent these hormones contribute to the pathologic expression of CHF. 
TABLE 3: Compensatory Mechanisms in Congestive Heart Failure 
Autonomic nervous system 
a. Heart 
i. Increased heart rate 
ii. Increased myocardial contractility 
iii. Increased rate of relaxation 
b. Peripheral circulation 
i. Arterial vasoconstriction (increased afterload) 
ii. Venous vasoconstriction (increased preload) 
Kidney: renin-angiotensin-aldosterone 
a. Arterial vasoconstriction (increased afterload) 
b. Sodium and water retention (increased preload and afterload) 
c. Increased myocardial contractility 
Frank-Starling law of the heart 
a. Increased end-diastolic fiber length (increased preload) 
b. Increased end-diastolic volume (increased preload) 
c. Increased end-diastolic pressure (increased preload) 
Left ventricular hypertrophy 
Peripheral oxygen supply 
a. Redistribution of cardiac output 
b. Altered oxygen-hemoglobin dissociation curve 
c. Increased oxygen extraction by tissues 
Anaerobic metabolism 
Adapted from Hurst JW, et al. The Heart, 6th ediition. New York: McGraw-Hill Book Company (1986), p.323 
These "compensatory" mechanisms operant in individuals with CHF (Table 3) 
serve to increase both preload (ventricular end-diastolic volume and pressure) and 
afterload (systemic vascular resistance and left ventricular wall tension). Although 
initially helpful in increasing stroke volume by the Frank-Starling mechanism and 
ensuring an adequate perfusion pressure to peripheral vascular beds, these peripheral 
and neurohumoral changes eventually serve to raise myocardial workload and oxygen 

demands. In cases of combined ischemic cardiomyopathy and heart failure, a vicious 
cycle may result whereby cardiac energy utilization is increasingly taxed, causing an 
imbalance between myocardial oxygen supply and demand. As a result the failing 
heart loses additional contractile reserve and is less able to overcome increases in 
filling pressures ana systemic vascular resistance. Further ventricular deterioration 
ensues, yielding the clinical phenomenon of "congestive heart failure begetting further 
congestive heart failure." 
In addition to the degree of left ventricular dysfunction and functional impairment, 
several clinical and laboratory abnormalities have been associated with reduced 
survival among CHF patients (5). These include the degree of hemodynamic 
derangement as expressed by cardiac index, left ventricular filling pressure and 
systemic vascular resistance (9); the extent of exercise intolerance (10); the presence 
of complex ventricular arrhythmias (5); decreased serum sodium levels below 120 
mEq/L (20); and elevated serum norepinephrine levels (21). Most patients with CHF 
who die do so as a result of either progressive hemodynamic deterioration or sudden 
ventricular tachyarrhythmias (11). 

5. OVERVIEW ON THE TREATMENT OF 
CONGESTIVE HEART FAILURE 
Major advances in the pharmacologic management of CHF have taken place in 
recent years, largely as a result of increased understanding of pathophysiology, 
improved precision in diagnosis, and increased awareness of the magnitude of the 
morbidity and mortality rates associated with this syndrome. The prinicipal goals of 
therapy for patients with congestive heart failure include: 
1) improved performance of the left ventricle and prevention of further 
myocardial dysfunction; 
2) improved exercise tolerance and quality of life; 
3) improved survival and reduced mortality secondary to progressive 
hemodynamic deterioration and/or ventricular arrhythmias. 
Traditional therapy consists of administering inotropic agents to enhance myocardial 
contractility along with diuretic drugs to rid the body of the excess salt and water. In 
addition, an increasing variety of vasodilating agents, including direct-acting 
vasodilators, angiotensin-converting enzyme inhibitors, alpha-blockers, beta-blockers, 
and, recently, calcium channel antagonists, has become available for the treatment of 
heart failure. 
Current medical therapy is aimed primarily at improving the derangements of the 
peripheral circulation, which relieves symptoms while leaving the primary myocardial 
insult unaffected. In cases of CHF due to ischemic cardiomyopathy, it may prove 
rewarding to develop additional medical therapeutic strategies aimed at minimizing 
any active ischemia contributing to the clinical state of congestive failure so as to 
prevent, delay, or reverse myocardial failure and, perhaps, morbidity and mortality. The 
following will be a discussion of available medical treatment options for CHF in the 
outpatient setting. 
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A. Inotropic Agents 
Pharmacotherapy of CHF was first introduced in 1788, when Withering reported 
clinical improvement in patients with "dropsy" after administration of foxglove (digitalis) 
(22) . Over the following two centuries, inotropic therapy has remained the cornerstone 
of therapy for heart failure. By inhibiting the Na+-K+ ATPase pump in myocardial cell 
membranes, digitalis and related glycosides, including digoxin, indirectly increase 
Na+-Ca++ exchange and, in so doing, increase intracytosolic calcium and contractility. 
Although not all patients appear to benefit from therapy, digoxin has been observed to 
exert favorable rest and exercise hemodynamic effects in many heart failure patients 
(23) . Patients with strikingly dilated left ventricles and/or ventricular diastolic gallops on 
exam represent those CHF patients having the most favorable response to the drug 
(24) . Clinical experience suggests that in some patients the major benefit from digitalis 
therapy may be secondary to a slowing of AV nodal conduction and ventricular 
response in those CHF patients with concomitant atrial fibrillation rather than from a 
positive inotropic effect per se. 
Recently, conflicting data has sparked a reevaluation of the precise therapeutic 
role of digitalis and digoxin. There have been reports suggesting that digoxin therapy 
might aggravate rhythm disturbances and actually increase mortality among CHF 
patients, especially those prone to ventricular ectopy and/or diuretic-induced 
hypokalemia (25). Nevertheless, further studies comparing digitalis with various 
therapeutic alternatives in CHF patients with normal sinus rhythm have reconfirmed 
these agents' value in improving left ventricular function while preventing a worsening 
of heart failure. 
B. Diuretics 
Diuretics, which became available for clinical use in the 1950s, represent the 
second important advance in the medical therapy of CHF. The loop diuretics, including 

furosemide, are generally the diuretic agents of choice with the administered dose 
carefully adjusted so as to maintain extracellular fluid volume at an optimal state. These 
agents act in the ascending limb of the loop of Henle, where approximately 25% of 
normal sodium reabsorption in the nephron occurs. Loop diuretics decrease pulmonary 
congestion and peripheral edema in CHF through venodilatation, reduction of left 
ventricular end-diastolic pressure (preload), and reduction of extracellular fluid 
overload. The efficacy of these drugs has been confirmed by numerous observations of 
improved cardiac performance, reduced pulmonary capillary wedge pressure, and 
resolved dyspnea and edema. 
However, the possibility of volume depletion and electrolyte imbalance following 
diuretic therapy also exists. Decreasing the preload may, in fact, reduce cardiac output 
and aggravate the symptoms of fatigue which result from inadequate peripheral blood 
flow. In addition, loop diuretic agents may cause excessive intravascular volume loss 
as well as potassium depletion, both of which may lead to continued plasma renin, 
arginine-vasopressin, and catecholamine secretion with secondary increases in 
peripheral vasoconstriction and afterload (26). 
C. Vasodilators 
Appreciation of the important role played by peripheral vasoconstriction in the 
pathophysiology of CHF has led to the development and widespread use of 
vasodilators as an additional treatment modality. Vasodilators function by reducing 
systemic vascular resistance via arteriolar and, in some instances, venous 
vasodilatation, thereby decreasing ventricular workload while increasing cardiac 
output. Symptoms attributable to a low flow state may be subsequently alleviated. In 
addition to producing significant symptomatic benefits, recent clinical trials of various 
vasodilator regimens have documented increased survival in some subgroups with 
advanced heart failure already receiving digoxin and diuretics (27). By countering 

rising systemic vascular resistances, vasodilator therapy tends to "unload" the failing 
heart and improve myocardial function while, to some extent, interrupting the otherwise 
downwardly spiraling course of left ventricular failure begetting more failure. 
Of the available vasodilators, the angiotensin-converting enzyme inhibitors, 
captopril and enalapril, appear to be the most effective. Acute administration of 
captopril results in an increase in cardiac output, a decrease in ventricular filling 
pressure, and an increase in renal blood flow (28). In double-blind, placebo-controlled, 
long-term trials of both captopril (29) and enalapril (30), patients randomized to receive 
angiotensin-converting enzyme inhibition improved both symptomatically and 
functionally when compared to control. In addition, experimental studies suggest that 
angiotensin-converting enzyme inhibitors may reduce the degree of ventricular 
remodeling which occurs following acute myocardial infarction (31). Indeed, the recent 
demonstration that the addition of enalapril to conventional therapy can significantly 
prolong life in patients with severe heart failure has led to the general conclusion that 
vasodilator drugs, and specifically the angiotensin-converting enzyme inhibitors, 
should form part of any medical armamentarium used for patients with advanced CHF 
unless there are contraindications such as hyperkalemia, renal insufficiency or renal 
artery stenosis (32). 
D. Combination Therapy 
Any of the three therapeutic classes of drugs, inotropic agents, diuretics, or 
vasodilators, can be used as first-line therapy for patients with CHF. Digoxin appears to 
be most effective in patients who have more severe heart failure, dilated hearts, a 
reduced ejection fraction, or CHF complicated by atrial fibrillation with a rapid 
ventricular response. If the patient has evidence of volume overload, systemic or 
pulmonary edema, it is likely that diuretics will be required. Angiotensin-converting 
enzyme inhibitors are the only agents associated with both decreased mortality and 
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improved clinical status, are speculated to slow the rate of hemodynamic deterioration, 
and are generally the vasodilators of choice in patients with congestive heart failure. 
In virtually all studies in which combination therapy with different classes of drugs 
has been used, it appears that their hemodynamic effects are generally additive (Figure 
3). This sets the stage for the gradual addition of agents as heart failure worsens with 
maximal medical therapy including representative agents from all three classes. 
FIGURE 3: Effects of Single and Combination Therapy on the 
Frank-Starling Relationship in Congestive Heart Failure 
Adapted from Parmley WW. Pathophysiology and Current Therapy of Congestive Heart Failure. 
J Am Coll Cardiol 13: 781, 1989. 

6. CALCIUM CHANNEL ANTAGONISTS IN THE TREATMENT OF 
CONGESTIVE HEART FAILURE 
Calcium channel antagonists have had a great impact on the practice of 
cardiology. These agents have added significantly to the treatment of angina pectoris, 
supraventricular arrhythmias, hypertension, Raynaud's and active peripheral vascular 
disease, and hypertrophic cardiomyopathy complicated by diastolic dysfunction. Less 
well described, however, is the imoact of calcium channel entry "blockers" in the 
treatment of CHF in the setting of iscnemic heart disease. Indeed, in those cases which 
active ischemia contributes to a state of myocardial dysfunction, agents which foster 
relaxation of coronary arteries and increased coronary perfusion may potentially have 
favorable effects. The calcium channel antagonists, particularly those of the 
dihydropyridine class, are potent vasodilators as well as proven anti-ischemic agents, 
reducing systemic vascular resistance and pulmonary capillary wedge pressure (due to 
their afterload-reducing properties), as well as decreasing coronary vascular resistance 
and improving the myocardial oxygen supply:demand ratio (33). 
The calcium "channel" represents a pore in the sarcolemma selective for calcium 
movement. The passage of calcium ions across this phospholipid membrane in both 
myocardial and vascular smooth muscle cells is critical for muscle contraction. Once 
inside the cardiac myoplasm, calcium is bound to troponin C, permitting actin-myosin 
interaction to occur. In vascular smooth muscle cells, calcium ions bind with calmodulin 
to form a complex which stimulates myosin light chain kinase to phosphorylate the 
myosin light chains and allow actin-myosin interaction. In both cell types, these 
respective chains of events promote muscle contraction. 
Calcium channel antagonists "block" the entry of calcium through the calcium 
channel in both myocardium and vascular smooth muscle, so that less calcium is 
available to the contractile apparatus in both tissues. The result is both a negative 

inotropic effect and vasodilation to greater or lesser degrees. In general, vascular 
smooth muscle cells are more sensitive to the effects of calcium blocking agents than 
are myocardial cells. Nevertheless, the use of calcium channel "blockers" in heart 
failure has thusfar been discouraged by many authors because of the documented 
potential of these drugs to exert negative inotropic effects, which may worsen left 
ventricular dysfunction in certain individuals. 
Although calcium antagonists are often considered a single class of drugs, it is 
becoming increasingly clear that the chemical structures, receptor affinities, and 
pharmacodynamic actions of these agents are diverse with varied spectra of clinical 
activity. Indeed, a practical method of differentiating the various agents with respect to 
their potential effects in heart failure is to contrast their relative pharmacodynamic 
actions on coronary and peripheral vascular tone versus myocardial contractility (Table 
4). 
TABLE 4: Differential Effects of the Available 
Calcium Channel Antagonists 
N Q. V 
Negative Inotropic Action (Reduced Contractility) + + ++ 
Peripheral Vasodilatation (Reduced Afterload) ++ + + 
Coronary Vasodilatation +++ ++ ++ 
Reflex Sympathetic Stimulation +++ + + 
N = Nifedipine (dihydropyridine class) 
D = Diltiazem (benzothiazepine class) 
V = Verapamil (phenylalkamine class) 
As a general rule the dihydropyridine class, including nifedipine and felodipine, 
represents the most potent vasodilating calcium channel antagonists while offering the 
least relative negative inotropic effect. The inhibition of arterial smooth muscle occurs at 
the level of arteriolar resistance vessels and large muscular arteries with only a modest 
dilating effect upon venous capacitance vessels (34). In patients with moderate to 
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severe congestive heart failure, acute administration of nifedipine produces a 
substantial fall in systemic vascular resistance, resulting in a significant increase in 
cardiac index and variable decreases in both left ventricular filling pressure and mean 
arterial pressure without alterations in heart rate (35). In chronic studies, however, no 
clear cut benefit has been documented. Additionally, CHF patients with "unpredictable” 
decreases in cardiac output and precipitation of pulmonary edema following nifedipine 
use have been reported, likely due to dose-dependent exaggerations in negative 
inotropic action (36) and/or failures to decrease systemic vascular resistance (37). 
In addition to the beneficial reduction in left ventricular afterload, dihydropyridine 
calcium channel antagonists offer coronary vasodilatatory action potentially beneficial 
to patients with concomitant congestive heart failure and myocardial ischemia. Such a 
combination of direct anti-ischemic action (decrease in coronary vascular resistance 
with subsequent increases in coronary blood flow and oxygen supply) with afterload 
reduction (decreased peripheral vascular resistance and left ventricular wall tension) 
may not only lead to a decrease, but in occasional settings perhaps a reversal, in 
ventricular dysfunction. Following nifedipine therapy in CHF patients, myocardial 
oxygen consumption has been observed to diminish while the myocardial 
arterio-venous oxygen difference is reduced, findings compatible with an improved 
oxygen supply:demand ratio (38). Improved coronary perfusion with subsequent 
improvement in the overall contractile state of a previously ischemic myocardium may 
even serve to blunt the minimal negative inotropic properties of these agents and 
prevent the precipitation of worsened left ventricular dysfunction and pulmonary edema 
(36). Indeed, the second generation dihydropyridine compounds, including felodipine, 
feature even greater vascular selectivity without clinically detectable inotropic effects, 
stimulating renewed interest in these calcium channel antagonists as a treatment 
option for patients with ischemic cardiomyopathy and congestive heart failure. 
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7. FELODIPINE, A SECOND GENERATION DIHYDROPYRIDINE 
CALCIUM CHANNEL ANTAGONIST 
Felodipine is a second generation dihydropyridine calcium channel antagonist 
and a structural analogue of nifedipine. Its chemical structure, 
[4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,7-ethoxycarbonylpyridine] (Figure 4), was 
originally synthesized with the aim of developing a new antihypertensive vasodilator 
believed to interact with calmodulin so as to inhibit transmembrane ionized calcium 
influx while selectively relaxing vascular smooth muscle. Clinical trials have since 
documented its effectiveness not only as an antihypertensive agent but also in the 
treatment of classic and variant angina pectoris, pulmonary hypertension, and 
Raynaud’s phenomenon. Additionally, 15 open-label and double-blind international 
studies of 200 CHF patients have provided some evidence for hemodynamic, 
functional, and symptomatic improvement with felodipine in heart failure (Table 5). 
FIGURE 4: Structural Formula of Felodipine 
H3C00C 
Cl 
Cl 
cooch2ch3 
H 
Felodipine 
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Felodipine is believed to modulate the influx of ionic calcium across cell 
membranes by interacting with calmodulin or other calcium-binding proteins found in 
the cytoplasm of vascular smooth muscle cells. Following binding with calcium, 
calmodulin is normally converted from an inactive to an active form able to influence 
various cellular processes as a second messenger. Calmodulin normally binds a 
maximum of 4 mol Ca++ per mol protein when assayed at high ionic strength. However, 
in a concentration of 4 mol felodipine per mol of calmodulin, the binding is reduced to 
approximately 2 mol Ca++ (39). This competitive binding of felodipine to calmodulin has 
been confirmed by NMR analysis to occur allosterically with at least one of the other 
calcium binding sites being altered as well. In fact, NMR analysis reveals that felodipine 
binds to calmodulin with a binding constant of 10+5 - 10+6/mol, comparable to that of 
ionized calcium (40). Hence, felodipine is believed to exert its vasodilatory effects by 
inhibiting calcium uptake at the level of cytoplasmic calmodulin rather than by 
"blocking" calcium channels directly. 
All of the currently available calcium channel antagonists dilate vascular smooth 
muscle while reducing myocardial contractility to various degrees. The relative potency 
of a specific agent on smooth versus cardiac muscle fibers is referred to as its "vascular 
selectivity." Initial in vitro studies showed that felodipine is greater than a hundred times 
more potent in inhibiting contraction of rat portal vein preparations as compared with 
paced rat papillary muscle residing in the same organ bath (41). Rat portal vein was 
chosen because it exhibits physiologic properties similar to those of arterial resistance 
vessels. Felodipine inhibited the vascular smooth muscle in concentrations roughly 
beginning at 10'8mol/L without any significant negative inotropic myocardial effect, 
which did not appear until the concentration was raised to IQ'5-4 mol/L, making for a 
vascular:myocardiai potency ratio of 118:1. In fact, its vascular selectivity is 
approximately eight times greater than that of nifedipine and sixteen times greater than 
that of diltiazem when the vascular selectivity of verapamil is taken as the comparative 
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standard (42). These pharmacologic properties of felodipine, highly vasoselective with 
negligible negative inotropic properties, suggest that it might be useful as an 
anti-ischemic agent in patients with ventricular dysfunction. 
In addition to the in vitro evidence demonstrating a vascular selectivity 
unsurpassed by other calcium channel antagonists, subsequent in vivo studies have 
revealed direct coronary vasodilatation following felodipine administration. 
Intracoronary injection of felodipine in open chest, anaesthetised pigs revealed that 
felodipine caused a 50% reduction in coronary vascular resistance when given in 
doses which did not affect regional cardiac wall motion (43). Subsequent clinical trials 
with human subjects have demonstrated felodipine's favorable hemodynamic profile. 
Felodipine was noted to produce dose-dependent reduction in coronary vascular 
resistance and increases in coronary sinus blood flow and oxygen content while 
significantly narrowing the myocardial arterio-venous oxygen difference in subjects 
with angiographically proven coronary artery disease (44,45). In a subsequent 
placebo-controlled, double-blind trial utilizing quantitative coronary angiography, 
felodipine was noted to increase vessel diameter in the vicinity of coronary obstructive 
lesions, producing significant dilatation of diseased coronary vessels both proximal 
and distal to the areas of stenosis (46). In addition, sustained increases in stroke 
volume and cardiac output without impairment of myocardial contractility were 
observed following felodipine therapy in angina patients receiving concomitant 
beta-blockade and fixed cardiac pacing to control against reflex sympathetic 
stimulation (47). These findings suggest that felodipine may have much to offer in the 
management of ischemic heart disease, creating reductions in coronary arterial 
resistance without accompanying deleterious effects upon myocardial contractility. 
Clinical studies evaluating the hemodynamic actions of felodipine among 
patients with heart failure have revealed significant benefits, including decreases in 
systemic vascular resistance and increases in stroke volume and cardiac output 
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without apparent negative inotropic effects. In patients with severe heart failure, 
felodipine was observed to cause an acute fall in mean arterial pressure from 91 to 68 
mm Hg, a decrease in pulmonary capillary pressure from 22 to 14 mm Hg, and an 
increase in cardiac index from 2.2 to 2.7 L7min/m2 (48). Repeated 5 mg oral doses of 
felodipine in eleven "severe CHF subjects (ten of whom had angiographically proven 
coronary artery disease) lead to significant dose dependent reduction in systemic 
vascular resistance, a greater than 50% increase in cardiac index, a mean decline in 
pulmonary capillary wedge pressure from 26 to 15 mm Hg (with a cumulative dose of 
15 mg), and no significant change in overall left ventricular contractility. In addition, a 
significant increase in coronary blood flow and decrease in myocardial oxygen 
consumption were reported (49). 
Recent trials utilizing double-blind, placebo-controlled designs in ambulant CHF 
patients have, for the most part, confirmed the hemodynamic, clinical, and symptomatic 
benefits with felodipine. When hemodynamic changes induced by felodipine were 
considered along with treadmill exercise tolerance at baseline, following 2 days of 
treatment, and at the conclusion of a four week treatment period, exercise duration was 
found to increase significantly after two days of therapy with continuation of the 
functional improvement throughout the remainder of the month. Of significance 
hemodynamically, heart rate was unchanged, mean arterial blood pressure was 
reduced, cardiac index was increased, and pulmonary capillary wedge pressure was 
decreased both acutely and upon conclusion of four weeks of therapy (50). 
Normalization of baroreflex control of vascular resistance has also been demonstrated, 
an effect of potential therapeutic importance in the chronic management of patients with 
heart failure (51). In a subsequent eight week, placebo-controlled, parallel group study 
involving CHF patients maintained on stable doses of digitalis and diuretic, felodipine 
(5-10 mg po BID) produced a 16% increase in cardiac output, 12% increase in stroke 
volume index, and 21% decrease in systemic vascular resistance as compared to 
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placebo. Additionally, treadmill exercise duration was significantly increased among 
those patients receiving felodipine, and 91% of felodipine-treated patients noted 
improvement in the level of dyspnea compared to 41% of patients in the control group 
(52). 
However, not all previous studies demonstrate such an abundance of beneficial 
results. In a three week, placebo-controlled trial, CHF patients who received 5-10 mg 
felodipine po BID exhibited a 16% increase in cardiac output, but without a significant 
improvement in blood pressure, heart rate, pulmonary capillary wedge pressure, 
exercise capacity, or symptoms when compared to control (53). Nonetheless, the 
numerous beneficial hemodynamic and metabolic effects of felodipine, as reported in 
the vast majority of clinical trials performed to date, suggest a potentially useful role for 
felodipine in the joint management of CHF and ischemic heart disease. 
In summary, felodipine is a second generation dihydropyridine calcium channel 
antagonist which possesses potent peripheral and coronary vasodilatory effects 
without causing significant myocardial inhibition or chronic reflexogenic tachycardia. 
Among patients suffering from coronary heart disease, felodipine demonstrated 
significant reductions in both peripheral and coronary arteriolar resistance with 
secondary increases in stroke volume and cardiac output. In 14 of 15 previous clinical 
trials involving 200 heart failure patients, felodipine (administered in doses ranging 
from 0.1 mg/kg boluses to 60 mg po daily divided into either BID or TID regimens for up 
to 6 months) has been observed to produce both acute and chronic improvements in 
rest and exercise hemodynamics (Table 5). Improved clinical status and increased 
exercise tolerance after 4 weeks and 8 weeks were also demonstrated during 
double-blind, placebo-controlled studies. Indeed, the combination of anti-ischemic 
action with a lack of myocardial inhibitory effect makes felodipine particularly attractive 
for use in patients suffering from both coronary artery disease and left ventricular 
dysfunction. However, no study performed to date has considered the efficacy of 
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felodipine as adjuvent anti-ischemic therapy for coronary patients suffering from CHF 
and already receiving maximal medical therapy, including an angiotensin converting 
enzyme inhibitor (afterload reduction), a diuretic (preload reduction), and an inotropic 
agent. 

TABLE 5: Felodipine CHF Studies 
Investiaator Pyrsas§s-2t Sludy Desian Dose Duration N Efesy 
Emanuelsson Hemodynamics 
(rest & exercise) 
Open, acute 0.1 mg/kg 1 day 10 Rest & 
exercise 
hemodynamics 
improved 
Tweddel 1) Hemodynamics 
(rest & atrial 
paced); 
2) coronary venous 
blood flow 
Open, acute 10 mg 1 day 14 Rest & paced 
hemodynamics 
improved; 
Coronary flow 
improved 
Tweddel Hemodynamics 
(rest & exercise) 
Open 10, 20 mg 1 month 8 Rest & 
exercise 
hemodynamics 
improved 
Binetti Hemodynamics 
(rest & exercise) 
Single-blind, 
placebo-control 
5 mg TID 
10 mg TID 
20 mg TID 
4 days 13 Rest & 
exercise 
hemodynamics 
improved 
Timmis Hemodynamics 
(+ coronary) 
Open, acute 5 mg TID 1 day 11 Hemodynamics, 
+ coronary, 
improved 
Timmis 1) Hemodynamics 
(rest & exercise) 
2) Exercise duration 
Open, chronic 10 mg BID 4 weeks 10 Rest & 
exercise 
hemodynamics 
improved; 
exercise 
duration 24% 
increased 
Svedburg 1) Hemodynamics 
(rest & exercise) 
2) Exercise duration 
Open, chronic 5-15 mg TID 4 weeks 9 Rest & 
exercise 
hemodynamics 
improved 
Tan 1) Hemodynamics 
(rest & exercise) 
2) Exercise duration 
Double-blind, 
crossover vs 
placebo 
10 mg BID 3 weeks 15 Rest & 
exercise 
cardiac index 
increased; 
hemodynamics 
& exercise 
duration not 
improved 
Jewitt 1) Hemodynamics 
(low & high dose, 
rest & exercise) 
2) Exercise duration 
Double-blind, 
crossover vs 
placebo 
2.5 mg BID 
or 
10 mg BID 
6 weeks 16 Hemodynamics 
improved; 
exercise 
duration 
14-41% 
increased 

TABLE 5: Felodipine CHF Studies (continued) 
Dunselman 1) Hemodynamics 
(rest & exercise) 
2) Exercise duration 
Double-blind, 
parallel vs 
placebo 
10 mg BID 8 weeks 23 Hemodynamics 
improved; 
exercise 
duration 27% 
increased; 
symptoms 
reduced 
Dunselman Hemodynamics 
(rest & exercise) 
Open 5-10 mg BID 6 months 10 Hemodynamics 
improved 
Kassis Hemodynamics 
(rest & tilt) 
Double-blind, 
crossover vs 
placebo 
10 mg BID 3 weeks 18 Resting & tilt 
hemodynamics 
improved 
Amtorp Hemodynamics 
(rest & tilt) 
Double-blind 
vs placebo 
10 mg BID 24 weeks 21 
Binetti Acute regional 
blood flow 
Acute 0.15 mg bolus, 
.0075 mg/min 
infusion 
1 day 8 Muscular & 
hepatic blood 
flow increased; 
heart rate & 
renal blood 
flow unchanged 
Muir Hemodynamics Open 0.1 mg/kg 1 dose 12 Hemodynamics 
improved 
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8. PURPOSE OF STUDY 
Based upon an understanding of pathophysiologic principles and the initial 
observations regarding felodipine therapy in CHF to date, the following hypotheses 
were drawn: 
1. Acute and subacute ischemia may contribute significantly to the 
chronic ventricular dysfunction seen in patients suffering from 
ischemic cardiomyopathy; 
2. While as pure vasodilators calcium channel antagonists are probably 
inferior to the angiotensin converting enzyme inhibitors in CHF, they 
may play an important role in patients with ongoing active ischemia 
by improving coronary perfusion; 
3. Felodipine, which offers vascular selectivity without negative 
inotropic properties, may prove safe and effective in this setting. 
Relatively few studies have addressed the long term clinical utility of the 
dihydropyridine calcium channel antagonists in congestive heart failure. Rather, most 
of the published data report hemodynamic effects, with attention primarily afforded to 
afterload reduction properties. Indeed, no other center to date has considered the 
potential anti-ischemic effects of these agents in CHF patients already 
hemodynamically optimized with combination preload reduction (diuretic therapy) and 
afterload reduction (angiotensin converting enzyme inhibition). 
The purpose of this study, therefore, is to evaluate the clinical usefulness of 
felodipine when added to enalapril, +/- furosemide, +/- digoxin in patients suffering from 
congestive heart failure secondary to ischemic cardiomyopathy with the following 
objectives: 

1 . To ascertain the occurrence of active ischemia and its relationship 
to rest and exercise left ventricular function in patients with 
congestive heart failure secondary to coronary artery disease; 
2. To evaluate the effects of felodipine as compared to placebo on 
symptoms, signs, functional status, exercise tolerance, active 
ischemia, and left ventricular function in this population; 
3. To evaluate the safety and tolerability of felodipine versus placebo 
in this population. 
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9. MATERIALS AND METHODS 
A. Location and Duration of Study 
The study was conducted out of the Congestive Heart Failure clinic, West Haven 
Veterans Affairs Medical Center, West Haven, CT. The study was completed between 
January, 1989, and January, 1990. 
B. Patient Population 
Fourteen male patients averaging 69 years of age (range = 58-83), with New 
York Heart Association (NYHA) class ll-lll CHF and antecedent coronary artery disease, 
were prospectively studied. All subjects were on stable doses of enalapril (5-20 
mg/day), +/- furosemide (0-120 mg/day), +/- digoxin (0-.250 mg/day) for at least six 
weeks prior to study entry. 
Patients were screened for heart failure by the classical signs and symptoms of 
dyspnea on exertion, fatigue, orthopnea, paroxysmal nocturnal dyspnea, rales, jugular 
venous distention, third heart sound or edema as well as meeting criteria for NYHA 
functional class II or III (Table 6). Only those CHF subjects with baseline resting left 
ventricular ejection fractions less than 45% and exercise tolerance times within a range 
of 2-15 minutes by the modified Naughton treadmill protocol were considered. 
TABLE 6: New York Heart Association Functional Classification (54) 
Class l=No limitation. Ordinary physical activity does not cause undue fatigue, dyspnea, 
palpitations, or angina. 
Class ll=Slight limitation of physical activity. Such patients are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain. 
Class lllsMarked limitation of physical activity. Although patients are comfortable at rest, 
less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. 
Class IV=lnability to carry on any physical activity without discomfort. Symptoms of cardiac 
insufficiency or angina are present even at rest.With any physical activity increased 
discomfort is experienced. 
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The history of coronary artery disease was established by either documentation 
of a prior myocardial infarction with diagnostic Q waves on EKG and/or past enzyme 
elevations, or a positive coronary angiogram demonstrating at least 70% obstruction in 
at least one major coronary artery. 
Subjects were all ambulatory at the time of study entry and capable of tolerating 
withdrawal of any concomitant anti-ischemic therapy, other than sublingual 
nitroglycerine as needed, without developing severe or unstable angina pectoris. They 
were not functionally limited by either angina or claudication. In addition, all subjects 
were free from potentially confounding medical conditions or concurrent medical 
regimens as detailed in Table 7. 
TABLE 7: Exclusion Criteria for Study Entry 
1. Renal insuficiency with serum creatinine > 2.5 mg/dl or potassium > 5.5 meq/L; 
2. Hepatic disease with elevated transaminases, bilirubin and/or alkaline phosphatase; 
3.Severe pulmonary disease requiring chronic therapy with bronchodilators 
(beta-agonists, anticholinergics, or theophylline) or steroids; 
4.Unstable angina pectoris or angina limiting exercise tolerance; 
5.Intermittent claudication limiting exercise; 
6. Hypotension with systolic blood pressure less than 95 mm Hg; 
7. Hypertension with blood pressure greater than 170/100 despite enalapril and 
diuretic therapy; 
8. Hemodynamically significant aortic or mitral valvular disease; 
9. Acute myocardial infarction within three months preceding study entry; 
10. Coronary bypass surgery or angioplasty within three months preceding study entry; 
11 .Cerebrovascular accident within six months preceding study entry; 
12. Documented history of cardiac arrest, ventricular fibrillation, or ventricular 
tachycardia exceeding 30 seconds in duration; 
13. Concurrent vasodilator therapy other than enalapril; 
14. Concurrent cimetidine or anticonvulsant therapy. 
C. Study Design 
This was a prospective, ten-week, double-blind, randomized, parallel, 
placebo-controlled study. Following an initial two-week, single-blind placebo, baseline 
period, subjects were randomized to receive either felodipine (2.5 mg po BID) or 
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matching placebo for two weeks, after which time the dose was either doubled (5.0 mg 
po BID) if blood pressure remained above 100/60 or else maintained (2.5 mg po BID) 
throughout the remainder of the eight week, double-blind, treatment period (Figure 5). 
Hence, the total study duration was approximately ten weeks. 
FIGURE 5: Study Design 
Digoxin* 
Diuretic 
Enalaprii 
Placebo 
2.5 mg 
Placebo 
Felodipine ER 
5.0 mg 
Wks. 
-4- 
+ 2** 8 
Baseline Double-blind Treatment 
* Optional 
**At end of Week +2, depending on BP, dosage may be titrated up to 
5.0 mg felodipine ER b.i.d. 
1. Baseline Period 
All subjects entered into the study having been on maximal medical therapy as 
prescribed by their regular internists or cardiologists (including various combinations of 
enalapril, furosemide, and digoxin) for at least six weeks prior to entering into the two 
week baseline period. At the initial visit a complete history was obtained and physical 
examination performed. All concomitant anti-ischemic therapy, except sublingual 
nitroglycerin, was withdrawn, and the subjects were started on placebo therapy at 2.5 
mg po BID dosing (single-blind phase of study). During the second week of baseline, 
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the following baseline tests were performed and data obtained: 
1 .New York Heart Association questionnaire to determine NYHA functional class; 
2. Dyspnea/fatigue questionnaire to determine severity of dyspnea/fatigue; 
3. Minnesota Quality of Life symptomatic questionnaire to quantitate quality of life; 
4.Serum chemistry panel for serum creatinine; 
5. Rest and exercise Equilibrium Radionuclide Angiocardiography (ERNA) to 
determine resting left ventricular ejection fraction and the change in LVEF at 
peak exercise compared to rest; 
6. 2-3 Exercise tolerance tests (modified Naughton protocol) to determine mean 
exercise tolerance time; 
7. Rest and exercise thallium-201 scintigraphy to determine extent of reversible 
myocardial ischemia (% Total LV area ischemic) and ratio of reversible ischemia 
to total myocardial perfusion defect area (% LV area at risk ischemic); 
8. 48 hour Hotter EKG monitoring to determine the incidence of spontaneous 
myocardial ischemia (both frequency and total duration of significant ST 
segment depressions). 
NYHA functional classification and dyspnea/fatigue index scores were 
determined by the investigator while the subjects completed the University of 
Minnesota Quality of Life symptomatic questionnaire themselves. The NYHA functional 
classification nonparametrically grades the severity of CHF by the level of activity at 
which dyspnea occurs from 1 (least severe) to 4 (most severe) (Table 6). In contrast, the 
dyspnea/fatigue index measures the impairment of customary activity by dyspnea 
and/or fatigue and was scored from 0-4 with regards to functional impairment, 
magnitude of task, and pace of task. These individual dyspnea/fatigue scores are later 
added so as to obtain an index score, ranging from 0-12, providing another measure of 
a patient's functional status. The University of Minnesota "Living with Heart Failure" 
Quality of Life questionnaire allows the subjects to rate from 0-5 the extent to which 
heart failure prevented them "from living as you wanted during the previous month" 
among 22 possible situations. The individual Quality of Life scores for these different 
situations were summed to obtain a total score, ranging from a possible 0 ("no" 
limitations) to 110 ("very much" limited). 
Equilibrium radionuclide angiocardiography (ERNA) studies, using a red blood 
cell labeling technique with technetium-99m pertechnetate and stannous 
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pyrophosphate, allow for definition of the boundaries of the heart and calculation of 
changes in chamber volume through the cardiac cycle, including left ventricular 
ejection fraction (55). Resting left ventricular ejection fraction was calculated as the 
mean of three 60 second acquisitions obtained with a high resolution parallel hole 
collimator camera angled in a left anterior oblique (LAO) projection while the subjects 
were in a supine position. Additional left ventricular ejection fraction determinations 
were made at peak exercise with subjects pedaling an attached bicycle apparatus at 
60-80 revolutions per minute. All images were recorded on Polaroid film for visual 
interpretation by an experienced reader without knowledge of clinical history or other 
test results. 
Subjects performed symptom-limited maximal exercise treadmill tests using the 
modified Naughton protocol (Table 8). Blood pressure and a 12-lead 
electrocardiogram were obtained every two minutes during exercise and every minute 
during recovery. Heart rate was monitored continuously. Exercise tolerance time was 
determined as a mean of two treadmill tests separated by at least 48 hours. If the two 
maximal exercise times failed to be within 10% of each other, a third such test was 
performed and averaged with the more similar previous exercise time. 
TABLE 8: Modified Naughton Protocol (56) 
Stage Speed (mi/hr) Grade (%) Time (min) 02 Consumption (ml/kg/min) 
i 1.0 0.0 2 9 
2 1.5 0.0 2 10 
3 2.0 3.5 2 12 
4 2.0 7.0 2 16 
5 2.0 10.5 2 18 
6 3.0 7.5 2 22 
7 3.0 10.5 2 26 
8 3.0 12.5 2 30 
One of the treadmill exercise tests was accompanied by stress-redistribution 
thallium-201 scintigraphy of the heart. Stress thallium imaging allows for accurate 
assessment of both the extent and duration of exercise-induced myocardial 
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hypoperfusion, with both a sensitivity and specifity exceeding 90% (57). Areas of active 
ischemia are able to be distinguished from areas of prior infarction depending on 
whether "cold," unperfused areas laiar "fill in" or not, respectively, following a four hour 
redistribution phase. Subjects began the exercise thallium study at least four hours 
after eating a meal, and all nitrates were halted for at least 24 hours prior to the test. 
Subjects were injected with 1.5 to 2 mCi of thallium-201 intravenously at peak exercise 
and continued to exercise for 1-2 additional minutes. Scintigraphic imaging was begun 
5 minutes after exercise (stress thallium study) and again 4 hours later (redistribution 
thallium study). Ten minute images were obtained in the anterior, left anterior oblique 
(45°), and left lateral (70°) projections. A scintillation camera equipped with 37 
photomultiplier tubes, a high resolution parallel hole collimator and a V4 inch sodium 
iodide crystal was used to record between 2,000-12,000 gamma emission counts. All 
images were recorded on Poloroid film for visual interpretation by an experienced 
reader without knowledge of clinical history or other test results. 
Quantification of decreased/absent coronary perfusion was obtained by subtracting 
the thallium-perfused ventricular area from a normal mean value previously calculated 
from volunteers without coronary artery disease in each of the anterior, 45°, and 70° 
imaging projections. These three respective scores were summed so as to determine 
the total coronary perfusion defect, which was expressed as a percentage of the total 
left ventricular area. Utilizing the results from both the stress and redistribution thallium 
studies, the area of reversible myocardial ischemia (% total LV area ischemic) was then 
calculated using the following formula: 
% Total LV area ischemic = (% LV area unperfused in stress Tl) - ( % LV area unperfused in redistribution Tl). 
In addition, a normalized ischemia index (% LV area at risk ischemic), relating the area 
of reversible ischemia to total myocardial area at risk immediately following exercise 
was calculated using the following formula: 
% LV area at risk ischemic = (% LV ischemic)/(% LV area unperfused in stress Tl) X 100%. 
Finally, a 48 hour Holter EKG recording was obtained for each subject at the 
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conclusion of the baseline period, which was sent to Cardio Data Systems, Inc. 
(Haddonfield, NJ) for computer-assisted detection of ST depressions of at least 0.1 mV 
(80 msec after the J-point) exceeding one minute with episodes separated by at least 
one minute. 
The results of each of the above baseline studies were pooled and analyzed to 
determine the comparibility between the treatment and control groups utilizing 
unpaired t-test analysis with p values less than 0.05 taken as determinants of statistical 
significance. Similiar analysis was performed for subgroups of subjects randomized to 
either felodipine and placebo and demonstrating greater than 10% reversible 
myocardial ischemia on baseline thallium-201 scintigraphy. In addition, correlational 
analysis between baseline variables was performed utilizing either Pearson parametric 
correlation analysis or the Spearmann nonparametric rank test with p values less than 
0.05 taken as determinants of statistical significance. 
2. Treatment Period 
After completion of the baseline period, patients were randomized by arbitrary 
allocation number to receive either felodipine 2.5 mg po BID or matching placebo at a 
subject ratio of 1:1 (double-blind phase of study). All participants received the first dose 
of the double-blinded study medication under close supervision in the CHF clinic at the 
West Haven Veterans Affairs Medicial Center for four hours during which blood 
pressure and heart rate were checked at hourly intervals. 
Each subject was seen at two week intervals over the ensuing eight weeks with a 
symptom review and physical examination performed at each visit. At the end of the 
second week, subjects with blood pressures above 100/60 were titrated to 5.0 mg po 
BID of either felodipine or placebo and continued at this dose for the remaining six 
weeks of the treatment period, while those subjects with blood pressures at the end of 
the second week below 100/60 were maintained on the 2.5 mg po BID dosage. The 
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baseline enalapril, digoxin, and diuretic doses were kept unchanged throughout the 
study period in all cases. At the conclusion of the eight-week treatment period, all 
studies performed during the baseline period were repeated in the same order and 
time of day. 
The results of eight weeks of therapy on each of the symptomatic, functional, and 
hemodynamic variables were pooled for the treatment and control groups. The mean 
end of study values were compared against corresponding baseline values for each 
variable within each respective subject group by paired t-test analysis. In addition, 
mean differences between baseline and end of study variables were compared 
between the treatment and control groups utilizing unpaired t-test analysis. All 
statistical tests were based upon two-sided hypotheses at the 5% level of significance. 
D. Informed Consent 
In accordance with U.S. Food and Drug Administration regulations and Yale 
University School of Medicine Human Investigations Committee guidelines, all subjects 
were provided with both an oral and written description of the study protocol, including 
potential attendant hazards. Written consent was obtained prior to entry. 
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10. RESULTS 
A. Baseline Clinical Data 
Of the initial fourteen subjects, seven were randomized to receive felodipine and 
seven were randomized to receive placebo. Refer to Table 9 for comparison baseline 
clinical data between treatment and control groups. Table 10 lists significant 
correlational relationships between different baseline variables pooled for the entire 
cohort of subjects. 
There were no statistically significant differences between treatment and control 
groups with respect to the baseline clinical data (Table 9). There were, however, a few 
aspects worth noting: mean New York Heart Association (NYHA) functional 
classification and Minnesota Quality of Life symptom questionnaire scores were slightly 
greater, and dyspnea/fatigue index scores were slightly less for the treatment group as 
a whole, reflecting worse (though not statistically significant) baseline function and 
symptomatology in the treatment group. In addition, the treatment group required a 
daily mean furosemide dose of 46.7 mg as compared with only 24.0 mg among those 
subjects destined to receive placebo, were only able to exercise for a mean 613.0 
seconds as compared with 681.4 seconds for the control group, and had a mean 
resting left ventricular ejection fraction of 25.3% as opposed to 34.9% among 
individuals receiving placebo; all of which is suggestive that the active treatment group 
had somewhat more severe symptoms and systolic dysfunction at baseline. However, 
the control group displayed less ventricular reserve, with a 3.1% decrement in LVEF 
from resting to peak exercise state as compared with a 2.0% rise among the treatment 
group. Those subjects randomized to the treatment group received oral felodipine at a 
total mean daily dose of 7.9 mg on a BID regimen. 
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TABLE 9: Baseline Demographic Data 
TREATMENT CONTROL SIGNIFICANT 
BASELINE VARIABLE GBQUElk-U* GROUP (N=7)‘ DIFFERENCE 
Age (years) 68.1 +/- 8.2 70.6 +/- 3.1 NS*“ 
Body Weight (lbs) 180.4 +/-31.6 175.4 +/- 29.4 NS 
Enalapril dose (mg/day) 12.9 +/- 7.0 12.1 +/- 12.5 NS 
Digoxin dose (mg/day) 0.20 +/-0.07 0.19 +/- 0.07 NS 
Furosemide dose (mg/day) 46.7 +/- 37.2 24.0 +/- 8.9 NS 
NYHA Class 2.7+/- 0.5 2.3 +/- 0.5 NS 
Dyspnea/Fatigue Index 7.1 +/- 1.3 8.4 +/- 1.7 NS 
Quality of Life Score 30.9 +/-19.8 25.3 +/- 18.0 NS 
Serum creatinine (mg/dl) 1.27 +/- 0.24 1.29 +/- 0.29 NS 
Systolic BP (mm Hg) 136.9 +/-19.5 124.9 +/- 7.6 NS 
Diastolic BP (mm Hg) 74.9 +/-10.9 68.9 +/- 10.7 NS 
Heart Rate (beats/min) 74.6 +/- 10.9 68.9 +/- 13.2 NS 
Rest LVEF (%) 25.3 +/- 6.2 34.9 +/- 7.7 NS 
Peak LVEF - Rest LVEF (%) 2.0 +/- 7.3 -3.1 +/-7.1 NS 
Mean ETT (sec) 613.0 +/- 162.3 681.4 +/- 163.6 NS 
# Subjects with (+) Thallium 7 7 
% Total LV area ischemic (%) 8.0+/- 7.1 8.0 +/- 6.9 NS 
% LV area at risk ischemic (%) 37.3 +/- 25.3 46.0 +/- 20.0 NS 
#Subjects with (+) Holter 1 2 
# ST Depressions/24 hours 1.4 +/-3.1 2.7 +/- 4.5 NS 
min ST Depression/24 hours 19.8 +/- 44.3 160.3+/- 325.2 NS 
‘Mean +/-1 standard deviation 
“Statistical significance determined by unpaired t-test (2-tailed) with p<.05 
“*NS = Not significant 
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TABLE 10: Correlations Between Baseline Variables (N=14) 
VARIABLE VARIABLE r* R*‘ SIGNIFICANCE*” 
Mean ETT (sec) 
Mean ETT (sec) 
NYHA Class 
Dyspnea/Fatigue Index 
-.762 
.722 
p<.02 
p<.01 
Dyspnea/Fatigue 
Dyspnea/Fatigue 
NYHA Class 
Quality of Life Score 
-.887 
-.460 
p<.01 
p<.10 
Rest LVEF (%) Quality of Life Score -.452 p<.10 
* r = Pearson parametric correlation coefficient 
**R = Spearman Rank nonparametric correlation coefficent as corrected forties 
*** Significance= Two-tail probability of significant difference by chance alone with p< 05 
TABLE 11: Baseline Reversible Myocardial Ischemia 
By Thallium-201 Scintigraphy 
TREATMENT GROUP (N=7) CONTROL GROUP (N=7) 
% Total LV Area Ischemic* % Total LV Area Ischemic* 
18% 19% 
15 16 
12 09 
07 04 
02 03 
01 03 
01 02 
Mean +/- S.D. 8.0 % +/- 7.1 8.0 % +/- 6.9 
*% Total LV Area Ischemic = estimated amount of left ventricular area demonstrating reversible perfusion 
defects with stress and redistribution thallium-201 scintigraphy of the heart 
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Correlation studies utilizing either Pearson parametric correlation analysis or the 
Spearmann nonparametric Rank test were performed to identify any statistically 
significant relationships between study variables prior to randomization (Table 10). 
Inverse relationships were noted to exist between NYHA functional class (IV = worst 
CHF) and both dyspnea/fatigue index score and mean exercise tolerance time (both of 
which decrease as the CHF worsens). In addition, a direct relationship between 
dyspnea/fatigue index scores and mean exercise tolerance times was observed. 
Inverse relationships approaching significance were also observed between the 
Minnesota Quality of Life questionnaire scores (which increase as CHF worsens) and 
both resting left ventricular ejection fractions and dyspnea/fatigue index scores. 
The extent of reversible myocardial ischemia, quantified as a percentage of total 
left ventricular area, was nearly identical between the treatment and control groups 
when analyzed as mean values. However, upon closer inspection there was 
considerable variability within the each respective group (Table 11). Indeed, only three 
out of seven individuals in the treatment group and two out of seven individuals in the 
control group had baseline thallium studies revealing greater than 10% reversible 
myocardial ischemia, a widely used criterion for reproducible reversible myocardial 
ischemia at the Yale-New Haven Hospital and the West Haven Veterans Affairs 
Medical Center nuclear medicine departments (from discussions with Frans Wackers, 
M.D., and Robert Soufer, M.D.). 
Subgroups of randomized patients with baseline reversible myocardial ischemia 
by thallium-201 scintigraphy exceeding 10% were also examined. Table 12 features 
the baseline clinical data of these treatment and control subgroups. As with the whole 
treatment and control groups, the two respective subgroups were near identical except 
that those in the treatment subgroup had greater mean furosemide requirements (70.0 
mg/day vs. 20.0 mg/day), shorter mean exercise tolerance time (552.8 sec vs. 670.8 
sec), and lower mean left ventricular ejection fraction at rest (23.7% vs. 37.5%), though 
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only the latter difference was statistically significant. The treatment subgroup received 
oral felodipine at a total mean daily dose of 8.3 mg on a BID regimen. There was no 
statistically significant difference between the mean felodipine dose received by the 
entire treatment group and that received by the treatment subgroup. 
TABLE 12: Subgroup Baseline Demographic Data 
TREATMENT PLACEBO SIGNIFICANT 
BASELINE VARIABLE GROUP <N=3)* GROUP (N=2r DIFFERENCE 
Age (years) 66.2 +/- 2.0 71.1 +/- 0.1 p<.05 
Body Weight (lbs) 158.2 +/- 5.3 181.0 +/- 17.0 NS“* 
Enalapril dose (mg/day) 11.7+/-7.6 5.0 +/- 0.0 NS 
Digoxin dose (mg/day) 0.21 +/- 0.07 0.25 +/- 0.0 NS 
Furosemide dose (mg/day) 70.0 +/- 70.7 20.0 +/- 0.0 NS 
NYHA Class 2.7 +/- 0.6 2.5 +/- 0.7 NS 
Dyspnea/Fatigue Index 7.3 +/- 1.5 8.5 +/- 3.5 NS 
Quality of Life Score 23.7 +/- 13.5 24.0 +/- 1.4 NS 
Serum creatinine (mg/dl) 1.27 +/- 0.31 1.20 +/- 0.14 NS 
Systolic BP (mm Hg) 134.7 +/- 17.5 123.0+/- 7.1 NS 
Diastolic BP (mm Hg) 78.0 +/- 9.2 71.0 +/- 4.2 NS 
Heart Rate (beats/min) 77.3 +/- 16.2 76.0 +/- 17.0 NS 
Rest LVEF (%) 23.7 +/- 4.5 37.5 +/- 3.5 p<.Q5 
Peak LVEF - Rest LVEF (%) 4.3 +/- 5.8 -0.5 +/-2.1 NS 
Mean ETT (sec) 552.8 +/- 163.0 670.8 +/- 242.2 NS 
# Subjects with (+) Thallium 3 2 
% Total LV area ischemic (%) 15.0 +/-3.0 17.5 +/- 2.1 NS 
% LV area at risk ischemic (%) 52.3 +/-19.7 57.5 +/- 13.4 NS 
# Subjects with (+) Hotter 0 1 
# ST Depressions/24 hours 0.0 +/- 0.0 11.0 +/- 0.0 - 
min ST Depression/24 hours 0.0 +/- 0.0 813.0 +/- 0.0 - 
‘Mean +/-1 standard deviation 
“Statistical significance determined by unpaired t-test (2-tailed) with p<.05 
***NS = Not significant 

42 
B. Incidence of Reversible Myocardial Ischemia 
Stress thallium-201 scintigraphy obtained at baseline revealed reversible 
thallium defects and exercise-induced myocardial ischemia in all 14 subjects. 5/12 
subjects had greater than 1 mm ST depressions in one or more precordial leads at 
peak exercise. 7/12 subjects demonstrated no significant electrocardiographic changes 
with exercise despite evidence of reversible ischemia by thallium scintigraphy. Two 
subjects had left bundle branch blocks preventing accurate assessment of ST segment 
changes. In none of the patients was the presence of ischemia accompanied by 
angina. Although there was a trend towards greater ischemic area correlating with the 
presence of positive EKG changes, there were no significant differences in either the 
extent or location of reversible ischemia as detected by stress-redistribution TI-201 
scintigraphy between those subjects with and without corresponding 
electrocardiographic evidence for exercise-induced ischemia (Tables 13,14). 
48 hour Holter EKG monitoring with ST segment analysis confirmed spontaneous 
myocardial ischemia in 3/5 of subjects demonstrating analagous changes on the 
treadmill. No patients with electrocardiographically silent ischemia at time of stress 
testing had significant ST segment depressions during Holter monitoring. 
TABLE 13: Detection of Myocardial Ischemia with Exercise 
Electrocardiography in Subjects with Reversible Perfusion Defects by 
Stress-Redistribution TI-201 Scintigraphy 
TI-201 (+) EXERCISE (-) EXERCISE SIGNIFICANT 
RESULT EKG (N=5)‘ EKG (N=7r DIFFERENCE 
% Total LV area ischemic (%) 9.4 +/- 7.8 5.4 +/- 6.1 NS“* 
% LV area at risk ischemic (%) 46.3 +/- 21.6 34.5 +/- 23.2 NS 
‘Mean +/-1 standard deviation 
“Statistical significance determined by unpaired t-test (2-tailed) with p< 05 
“*NS = Not significant 

TABLE 14: Distribution of Reversible Perfusion Defects by TI-201 
Scintigraphy in Subjects with & without Exercise 
Electrocardiographic Evidence for Myocardial Ischemia 
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AREA OF REVERSIBLE (+) EXERCISE (-) EXERCISE 
ISCHEMIA ON TI-201 EKG(N=5)* EKG (N=7)“ 
Anterior 40% 29% 
Anterolateral 20 00 
Anterobasal 20 14 
Anteroseptal 00 29 
Inferior 20 57 
Inferolateral 60 29 
Inferoseptal 40 29 
Apiclal 40 71 
Basoseptal 40 29 
Posterolateral 60 14 
Posteroseptal 20 14 
Posterobasal 20 14 
‘Percentage of subjects with (+) EKG signs of exercise-induced ischemia 
“Percentage of subjects without (+) EKG signs of exercise-induced ischemia 
C. Effects on Reversible Myocardial Ischemia 
Effects of felodipine therapy on reversibly ischemic area were evaluated for the 
treatment group and subgroup as well as compared against the control group and 
subgroup respectively. Reversible myocardial perfusion defects noted on stress and 
redistribution thallium-201 scintigraphy were not found to significantly decrease in the 
treatment vs. control groups (Tables 15-17). However, among the subgroups of 
subjects with baseline thallium scans revealing greater than 10% reversible perfusion 
defects, felodipine did significantly improve myocardial perfusion (Tables 18-20). The 
mean % total LV area which was ischemic in the treatment subgroup decreased from a 
mean of 15.0% +/- 3.0 at baseline to 5.3% +/- 3.5 following eight weeks of felodipine 
treatment, approaching statistical significance (Figure 6). In addit. i, the mean % LV 
area at risk which was ischemic decreased significantly among the treatment subgroup 
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from 52.3% +/- 19.7 at baseline to 23.3% +/- 26.1 at the conclusion of the study period 
(Figure 7). This latter improvement also approaches statistical significance when 
compared to reciprocal changes in the control subgroup. 
D. Effects on Systemic Blood Pressure & Heart Rate 
Eight weeks of felodipine therapy significantly reduced mean systolic pressure by 
19.7 mm Hg (from 136.9 to 117.1 mm Hg) and reduced mean diastolic pressure by 5.4 
mm Hg (from 74.9 to 69.4 mm Hg) in the treatment group (Tables 15-17). These 
reductions represent significant changes over those noted in the control group. In 
contrast, mean heart rate was not affected. 
The treatment subgroup also demonstrated significant reductions in mean 
systolic pressure (from 134.7 to 118.0 mm Hg) and mean diastolic pressure (from 78.0 
to 70.0 mm Hg) without accompanying changes in mean heart rate (Table 18). 
E. Effects on Rest & Peak Exercise LVEF 
No deleterious effects upon systolic cardiac performance, as reflected in mean 
left ventricular ejection fractions obtained at rest and at peak exercise, were noted 
following eight weeks of felodipine therapy when compared either to baseline or to 
subjects receiving placebo (Tables 15-17). In fact, mean resting LVEF increased from 
27.3% to 30.1 in the treatment group and from 26.4% to 30.7 in the treatment subgroup 
(though neither change was statistically significant). In the control group and subgroup 
there were little changes in mean resting LVEF (from 35.6% to 34.1 and from 36.0% to 
38.0, respectively). 
F. Effects on Exercise Tolerance 
Mean exercise tolerance time using the modified Naughton protocol for treadmill 
exercise testing did not significantly increase among either the treatment or control 
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groups (Tables 15-17). However, a trend towards greater functional improvement 
following felodipine therapy in those subjects with baseline myocardial ischemia 
exceeding 10% was demonstrated as the mean exercise tolerance time improved by 
over half of a minute (36.2 sec) in the treatment subgroup while falling by over half a 
minute (37.3 sec) in the control subgroup (Tables 18-20). 
G. Effects on Symptomatic & Functional Status 
No significant changes in either functional status (NYHA class), severity of limiting 
symptoms (dyspnea/fatigue index), or quality of life (University of Minnesota 
questionnaire) were found to occur among subjects receiving eight week felodipine 
therapy as compared with baseline or to subjects receiving placebo (Tables 15-17). 
H. Safety & Tolerability 
Felodipine, administered at doses ranging between 2.5-5.0 mg po BID, caused 
no untoward side effects among the seven individuals randomized to the treatment 
group necessitating discontinuation of the drug and withdrawal from the study. One 
subject in the treatment group (receiving 5.0 mg of felodipine po BID) was noted to 
develop worsening pedal edema in weeks 6-8 of the study which was unassociated 
with any other clinical symptoms or signs of worsening CHF. 
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TABLE 15: Efficacy Data Comparing Treatment Group (N=7) 
at Baseline & End of Study 
SIGNIFICANT 
VARIABLE BASELINE VALUE* 8 WEEK VALUE* DIFFERENCE’ 
NYHA Class 2.7 +/- 0.5 2.7 +/- 0.5 NS*** 
Dyspnea/Fatigue Index 7.1 +/- 1.3 7.4 +/- 1.9 NS 
Quality of Life Score 30.9 +/- 19.8 27.9 +/- 21.5 NS 
Serum creatinine (mg/dl) 1.27+/-0.24 1.36 +/- 0.17 NS 
Systolic BP (mm Hg) 136.9 +/- 19.5 117.1 +/- 16.3 p<.001 
Diastolic BP (mm Hg) 74.9 +/- 10.9 69.4 +/- 9.6 NS 
Heart Rate (beats/min) 74.6 +/- 10.9 78.9 +/- 8.6 NS 
Rest LVEF (%) 27.3 +/- 6.4 30.1 +/- 9.0 NS 
Peak LVEF - Rest LVEF (%) 2.0 +/- 7.3 0.3 +/- 5.5 NS 
Mean ETT (sec) 613.0 +/- 162.3 638.0 +/- 152.5 NS 
% Total LV area ischemic (%) 8.0+/- 7.1 5.0 +/- 4.6 NS 
% LV area at risk ischemic (%) 37.3 +/- 25.3 22.1 +/- 28.3 NS 
* Mean +/-1 standard deviation 
** Statistical significance determined by paired t-test (2-tailed) with p<.05 
*** NS = Not significant 

47 
TABLE 16: Efficacy Data Comparing Control Group (N=7) 
at Baseline & End of Study 
VARIABLE BASELINE VALUE* 8 WEEK VALUE* 
SIGNIFICANT 
DIFFERENCE 
NYHA Class 2.3 +/- 0.5 2.3 +/- 0.5 NS*** 
Dyspnea/Fatigue Index 8.4 +/- 1.7 9.0 +/- 2.6 NS 
Quality of Life Score 25.3 +/- 18.0 13.6 +/- 10.5 p<.02 
Serum creatinine (mg/dl) 1.29 +/-0.29 1.34 +/- 0.41 NS 
Systolic BP (mm Hg) 124.9 +/- 7.6 122.3 +/- 11.1 NS 
Diastolic BP (mm Hg) 68.9 +/- 10.7 74.0 +/- 8.7 NS 
Heart Rate (beats/min) 68.9 +/- 13.2 74.6 +/- 8.8 NS 
Rest LVEF (%) 35.6 +/-8.1 34.1 +/- 9.0 NS 
Peak LVEF - Rest LVEF (%) -3.1 +/- 7.1 1.3+/-6.9 p<.05 
Mean ETT (sec) 681.4 +/- 163.6 688.0 +/- 137.9 NS 
% Total LV area ischemic (%) 8.0 +/- 6.9 5.0 +/- 4.9 NS 
% LV area at risk ischemic (%) 46.0 +/- 20.0 27.0 +/- 24.4 NS 
* Mean +/-1 standard deviation 
** Statistical significance determined by paired t-test (2-tailed) with p<.05 
*** NS = Not significant 

TABLE 17: Efficacy Data Comparing Treatment & Control Groups 
TREATMENT CONTROL SIGNIFICANT 
DELTA VARIABLE* GROUP fN=7 GROUP (N=71“ DIFFERENCE 
NYHA Class 0.0 +/- 0.6 0.0 +/- 0.0 NS““ 
Dyspnea/Fatigue Index 0.3 +/- 2.5 0.6 +/- 1.9 NS 
Quality of Life Score 
-3.0 +/- 13.4 
-11.7 +/- 9.5 NS 
Serum creatinine (mg/dl) 0.09 +/- 0.11 0.06 +/- 0.19 NS 
Systolic BP (mm Hg) 
-19.7 +/- 8.3 
-2.6 +/- 7.5 p<.01 
Diastolic BP (mm Hg) 
-5.4 +/- 6.5 5.1 +/- 11.2 p<.05 
Heart Rate (beats/min) 4.3 +/- 11.2 5.7 +/- 7.3 NS 
Rest LVEF (%) 2.9 +/- 6.6 
-1.4+/- 5.4 NS 
Peak LVEF (%) 1.1 +/- 13.0 3.0 +/- 6.4 NS 
Mean ETT (sec) 25.0+/- 71.1 6.6 +/- 70.7 NS 
% Total LV area ischemic (%) -3.0 +/- 9.0 -3.0 +/- 5.1 NS 
% LV area at risk ischemic (%) -15.2 +/- 39.3 
-19.0 +/-30.0 NS 
* Delta = End of Study value- Baseline value 
“Mean +/-1 standard deviation 
“‘Statistical significance determined by unpaired t-test (2-tailed) with p<.05 
““NS = Not significant 
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TABLE 18: Efficacy Data Comparing Treatment Subgroup (N=3) 
at Baseline & End of Study 
VARIABLE BASELINE VALUE* 8 WEEK VALUE* 
SIGNIFICANT 
DIFFERENCE 
NYHA Class 2.7 +/- 0.6 2.7 +/- 0.6 NS*** 
Dyspnea/Fatigue Index 7.3 +/- 1.5 8.3 +/- 2.5 NS 
Quality of Life Score 23.7 +/- 13.5 20.0 +/- 14.8 NS 
Serum creatinine (mg/dl) 1.27 +/-0.31 1.33 +/- 0.25 NS 
Systolic BP (mm Hg) 134.7 +/- 17.5 118.0 +/- 20.8 p<.05 
Diastolic BP (mm Hg) 78.0 +/- 9.2 70.0 +/- 10.0 p<.05 
Heart Rate (beats/min) 77.3 +/- 16.2 74.7 +/- 9.2 NS 
Rest LVEF (%) 26.4 +/- 4.0 30.7 +/- 11.5 NS 
Peak LVEF - Rest LVEF (%) 4.3 +/- 5.8 0.0 +/- 6.6 NS 
Mean ETT (sec) 552.8 +/- 163.0 589.0 +/- 57.9 NS 
% Total LV area ischemic (%) 15.0 +/-3.0 5.3 +/- 3.5 p<.10 
% LV area at risk ischemic (%) 52.3 +/- 19.7 23.3 +/- 26.1 p<05 
* Mean +/-1 standard deviation 
** Statistical significance determined by paired t-test (2-tailed) with p<.05 
*** NS = Not significant 
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TABLE 19: Efficacy Data Comparing Control Subgroup (N=2) 
at Baseline & End of Study 
VARIABLE BASELINE VALUE* 8 WEEK VALUE* 
SIGNIFICANT 
DIFFERENCE 
NYHA Class 2.5 +/- 0.7 2.5 +/- 0.7 NS*** 
Dyspnea/Fatigue Index 8.5 +/- 3.5 8.0 +/- 4.2 NS 
Quality of Life Score 24.0 +/- 1.4 17.5 +/- 7.8 NS 
Serum creatinine (mg/dl) 1.20 +/- 0.14 1.25 +/- 0.35 NS 
Systolic BP (mm Hg) 123.0 +/- 7.1 123.0 +/- 15.6 NS 
Diastolic BP (mm Hg) 71.0 +/- 4.2 76.0 +/- 14.1 NS 
Heart Rate (beats/min) 76.0 +/- 17.0 75.0 +/- 12.7 NS 
Rest LVEF (%) 36.0 +/- 5.7 38.0 +/- 2.8 NS 
Peak LVEF - Rest LVEF (%) -0.5 +/- 2.1 3.5 +/- 2.1 NS 
Mean ETT (sec) 670.8 +/- 242.2 633.5 +/- 218.5 NS 
% Total LV area ischemic (%) 17.5 +/-2.1 10.5 +/- 3.5 NS 
% LV area at risk ischemic (%) 57.5 +/-13.4 45.0 +/- 7.1 NS 
* Mean +/-1 standard deviation 
** Statistical significance determined by paired t-test (2-tailed) with p< 05 
*** NS = Not significant 

TABLE 20: Efficacy Data Comparing Treatment & Control Subgroups 
TREATMENT CONTROL SIGNIFICANT 
DELTA VARIABLE* GROUP (N=31“ GROUP (N=2r* DIFFERENCE 
NYHA Class 0.0 +/- 1.0 0.0 +/- 0.0 NS 
Dyspnea/Fatigue Index 1.0 +/- 3.6 
-0.5 +/- 0.7 NS 
Quality of Life Score 
-3.7 +/-20.8 -6.5 +/- 6.4 NS 
Serum creatinine (mg/dl) 0.07 +/-0.06 0.05 +/- 0.21 NS 
Systolic BP (mm Hg) 
-16.7 +/- 6.4 0.0 +/- 8.5 p<.10 
Diastolic BP (mm Hg) 
-8.0 +/- 2.0 5.0 +/- 9.9 P<.10 
Heart Rate (beats/min) 
-2.7 +/- 8.3 
-1.0 +7-4.2 NS 
Rest LVEF (%) 4.7+/- 7.5 2.0 +/- 2.8 NS 
Peak LVEF (%) 0.3 +/- 5.8 -1.0 +/- 2.8 NS 
Mean ETT (sec) 36.2 +/- 105.2 
-37.3 +/- 23.7 NS 
% Total LV area ischemic (%) -9.7 +/- 5.5 -7.0 +/- 5.7 NS 
% LV area at risk ischemic (%) -29.0 +/- 9.5 -12.5 +/- 6.2 p<.10 
* Delta = End of Study value- Baseline value 
“Mean +/- 1 standard deviation 
“‘Statistical significance determined by unpaired t-test (2-tailed) with p<.10 
““NS = Not significant 
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FIGURE 6: % Total LV Area Ischemic 
in Treatment and Control Subgroups 
at Baseline & Following 8 Wk Therapy 
Rx baseline Rx 8 wks Ctrl baseline Ctrl 8 wks 
Subgroups 
S3 i s.d. 
Mean 
* p<.10 vs. baseline 

80 
60 
40 
20 
0 
FIGURE 7: % LV Area at Risk Ischemic 
in Treatment and Control Subgroups 
at Baseline & Following 8 Wk Therapy 
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11. DISCUSSION 
Alterations in preload, afterload, and contractility provide the basis for the 
available therapeutic interventions employed in the standard treatment of CHF. In CHF 
the normal Frank-Starling ventricular reserve is depressed (Figure 1). Inotropic agents 
shift the Frank-Starling preload-to-contractility relationship such that greater stroke 
volumes occur with lower ventricular filling pressures. Diuretics decrease left 
ventricular end-diastolic pressure and preload but do not improve cardiac output. 
Afterload reduction with vasodilator therapy offers the possibility of increased cardiac 
output while decreasing the cardiac workload. Yet, despite combination therapy with 
these three classes of medical agents, the underlying heart disease remains 
progressive in most patients, with only palliation of the peripheral manifestations of 
heart failure and symptomatic improvement being achieved. Only vasodilator therapy 
has been observed to correlate positively with improved survival rates. 
This study has shown that pharmacologic intervention aimed at both afterload 
modulation and relief of ischemia may have promise in the treatment of ischemic 
cardiomyopathy and CHF. Felodipine is a dihydropyridine calcium channel antagonist 
which reduces peripheral, coronary, and pulmonary vascular resistance. In addition, 
felodipine is highly vasoselective, exerting minimal depressant effect on myocardial 
contractility. Indeed, its afterload reducing properties and apparent lack of clinically 
important negative inotropic effects have made it attractive for use as an anti-ischemic 
agent in coronary patients with left ventricular dysfunction and congestive heart failure. 
In previous hemodynamic studies of CHF patients on stable doses of digoxin and 
diuretic, additional therapy with felodipine produced a persistent reduction in vascular 
resistance and an increase in cardiac output, both at rest and during exercise. In 
several reports, a decrease in pulmonary capillary wedge pressure during exercise has 
also been observed. Yet, in other studies, correlations with increased exercise 
tolerance and symptomatic improvement were not found, bringing into question the 
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practical utility of this agent. In the present study, felodipine was investigated as 
"add-on therapy" to patients with CHF secondary to coronary artery disease and 
symptomatic despite standard maximal medical therapy including enalapril. In so 
doing, it was postulated that any gains realized would be at least partially attributable to 
improvement in coronary perfusion and reversal of active myocardial ischemia rather 
than wholly to afterload reduction. 
A. Prevalence of Clinically & Electrocardiographically Silent Ischemia 
The finding of active myocardial ischemia by thallium-201 scintigraphy coupled 
with an absence of exercise-limiting angina in all of the subjects, as well as a lack of 
electrocardiographic evidence for ischemia in a majority of the subjects, were 
unexpected observations from this study. These phenomena of "clinically silent" and 
"electrocardiographically silent" myocardial ischemia have been previously reported in 
coronary patients. However, the relative incidence of silent ischemia among patients 
limited by symptoms of CHF has yet to be reported. 
"Silent" or asymptomatic myocardial ischemia was first identified as a clinical 
entity in the 1970's. Lindsey and Cohn reported that 26% of patients with coronary 
artery disease, documented by cardiac catheterization, had ischemic EKG responses to 
exercise testing without accompanying chest pain or anginal equivalents (58). 
Subsequent estimates of silent ischemia among patients with a history of myocardial 
infarction have ranged between 47-76% with similiar criteria of positive ST segment 
depressions in the absence of anginal pain (59-62). In the present study, 5 out of 12 
subjects without left bundle branch block (41.7%) demonstrated asymptomatic ST 
segment depressions with exercise. Ambulatory EKG monitoring with ST segment 
analysis was also undertaken in an attempt to obtain an objective measure of transient 
ischemia during daily life. Three of the 5 subjects with exercise-induced ST 
depressions also had spontaneous ST segment changes recorded on ambulatory EKG 
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monitoring while no subjects with baseline exercise tests lacking EKG changes 
demonstrated evidence for ischemic episodes on ambulatory EKG analysis. ST 
segment depressions have also been difficult to reproduce in previous experimental 
studies, having been recorded intermittently from the edge of ischemic segments, on 
patches of pericardium during endocardial ischemia, and from the ventricular wall 
opposite an ischemic segment (63-65). Thus, electrocardiographic evidence for ST 
segment depression may represent an insensitive marker of transient ischemia. 
In the remaining 7 of 12 subjects without left bundle branch blocks (58.3%), there 
was no electrocardiographic evidence for myocardial ischemia by either exercise EKG 
or ambulatory EKG monitoring despite scintigraphic evidence for reversible coronary 
perfusion defects. In the only other studies utilizing thallium-201 perfusion defects and 
the absence of angina as critieria for silent ischemia, Assey et al. reported a similiar 
incidence of negative EKG responses to exercise (59%), while Gibson found that 55% 
of patients and Hecht et al. reported 68% of patients with electrocardiographically silent 
ischemia (66-68). These findings confirm the relative insensitivity of 12-lead EKG 
monitoring as compared to thallium scintigraphy for detection of myocardial ischemia 
(69-71). A possible explanation for electrocardiographically silent ischemia may 
involve the magnitude of inducible ischemia: conceptually, a threshold of ischemic area 
may be necessary to produce electrocardiographic change. Anatomic localization of 
exercise-induced ischemia is another potential explanation for electrocardiographically 
silent ischemia (72). Neither relation was confirmed by the present study (Tables 
13,14). 
Unfortunately, there is no widely available "gold standard" to validate the 
accuracy of noninvasive tests in delineating myocardial ischemia. However, most 
published reports on silent myocardial ischemia have used the presence or absence of 
ST depression to define ischemia while excluding from consideration those patients 
without ST depression. The present study demonstrates that the amount and 
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distribution of reversibly ischemic myocardium may in fact be similiar in patients with 
and without exercise-induced ST depression. Consequently, studies that have relied 
solely on electrocardiographic criteria have probably greatly underestimated the 
number of patients with silent ischemia. Results from the present study highlight the 
inaccuracy that may follow conventional EKG stress testing not accompanied by angina 
and/or ST segment depression. 
B.Reduction of Reversible Myocardial Ischemia 
Reversible areas of coronary hypoperfusion detected by thallium scintigraphy 
may reflect the overall magnitude of myocardial area at risk for future infarction and, 
hence, the potential for worsened pump failure and possible creation of 
arrhythmogenic foci. Previous in vitro and in vivo studies have revealed direct coronary 
vasodilation following felodipine administration (46), while hemodynamic studies have 
confirmed the coronary vasodilatory properties of felodipine in man (47-49). 
Whether or not maximal medical therapy with enalapril, furosemide, and/or 
digoxin alters the balance between myocardial oxygen supply and demand in such a 
collection of patients was not addressed by this study. Rather, the addition of felodipine 
(5.0-10.0 mg/day) to such a medical regimen was observed to significantly reduce the 
amount of reversible ischemia as detected by thallium scintigraphy in the treatment 
subgroup (including patients with baseline reversible defects exceeding 10%). A 
normalized ischemia index was calculated for each subject as the % LV area at risk 
which was ischemic. This index may represent a more physiologic gauge for potential 
therapy than % total LV area which was ischemic, as it reflects the extent to which 
diseased myocardium represents salvagable versus irreversibly scarred, infarcted 
tissue. Indeed, significant decreases in the normalized ischemia index were observed 
following felodipine administration in the treatment subgroup as compared with 
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baseline (Table 18, Figure 7). This decrease was also found to approach statistical 
significance when compared to the control subgroup (Table 20). 
Whether or not felodipine is equally effective for patients with smaller initial 
defects remains unknown given the statistical constraints of the study. More subjects 
will be needed before any firm conclusions may be drawn regarding the effects of 
felodipine upon reversible ischemia in all patients with concomitant ischemic 
cardiomyopathy and CHF. Indeed, this preliminary study is intended to assist in the 
identification of new inclusion criteria and promising clinical markers for future 
investigation. 
C. Absence of Deleterious Effects upon Ventricular Function 
Felodipine administration was not accompanied by a further decline in left 
ventricular function. Rather, mean resting left ventricular ejection fraction appear to 
have improved in the treatment group as compared to the control group. In addition, 
there exists an important trend to be noted: the subgroup of subjects with baseline 
perfusion defects exceeding 10% had the largest improvement in mean left ventricular 
ejection fraction following felodipine therapy. Perhaps the relative gains made in left 
ventricular ejection fraction indirectly reflect the significant reduction in reversible 
ischemia (see section B) and/or systolic and diastolic blood pressures (see section D) 
observed in this subgroup and result from similiar improvements in the myocardial 
oxygen supply:demand ratio and contractility. 
D. Afterload Reduction 
In addition to acting as a coronary vasodilator, felodipine lowers systemic 
vascular resistance and clinically may serve as a potent afterload reducer. In the 
present study both systolic and diastolic blood pressure were noted to fall significantly 
following chronic felodipine therapy as compared with placebo (Table 17). In contrast, 
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the control group showed no significant hemodynamic changes. Though not directly 
measured in this study, these changes may contribute to an improvement in the 
myocardial oxygen supply:demand ratio via afterload reduction (decreasing systemic 
vascular resistance) in addition to that attributable to direct anti-ischemic action 
(decreasing coronary artery vascular resistance). 
E. Improvement in Exercise Tolerance 
Maximal exercise tolerance, measured with the modified Naughton treadmill 
protocol and quantified as total exercise duration, has proved to be a useful index of 
functional status in patients with CHF (73). An increase of exercise capacity has indeed 
become an essential requirement for proof of drug efficacy in many clinical trials; this 
despite the questionable suitability of such "maximum" stress tests to patients with heart 
failure. The justification for such a test is the a priori belief that patients can achieve a 
maximal oxygen consumption which is an indicator of their overall physical capacity 
limited by the cardiovascular system (74). Examination of the baseline data indeed 
confirmed an inverse correlation between the maximum exercise stage completed and 
NYHA functional class. 
Dyspnea and fatigue were the symptoms which limited physical activity in the 
subjects studied. The precise cause of these symptoms remains uncertain (75,76). 
Because of the limited cardiac output state in ischemia-related CHF, rising pulmonary 
vascular pressures and redistribution of peripheral blood flow away from skeletal 
muscle would be expected to occur with increasing exercise. By primarily acting on 
arteriolar smooth muscle, the dihydropyridine calcium channel antagonists are known 
to counteract the compensatory vasoconstrictive reflex following congestive cardiac 
failure and, in so doing, limit secondary rises in oxygen extraction, anaerobic 
metabolism, accumulation of lactic acid, and local symptoms, while increasing duration 
of exercise to exhaustion (50). However, in patients already being treated with 
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angiotensin-converting enzyme inhibition (enalapril 5-20 mg/day), further improvement 
in regional hemodynamic changes may not be possible, resulting in suboptimal 
delivery of blood to exercising muscle and reappearance of symptoms. In the present 
study, such an addition of felodipine to combination medical therapy failed to 
significantly increase mean exercise tolerance time on the treadmill. However, the 36 
second gain (or, roughly, quarter of a stage in the modified Naughton protocol) made 
by the treatment subgroup versus the 37 second decline seen in the control subgroup 
following eight weeks of therapy (Table 20) represents a promising trend which needs 
to be followed up with additional subjects in order to achieve statistical significance. 
F. Unchanged Functional & Symptomatic Status 
One of the goals of therapy in patients with chronic heart failure is improvement in 
symptoms, stabilization or improvement in functional abilities, and improved comfort for 
the remaining duration of life. During the past decade, there has been increasing 
documentation of the scientific validity of global quality of life measures which quantify 
and reliably describe a variety of subjective features of health status (77). In the present 
study three such tests were utilized: the NYHA functional classification, the 
dyspnea/fatigue index, and the University of Minnesota Quality of Life symptom 
questionnaire. 
Poor correlation has repeatedly been demonstrated between measures of 
ventricular performance (including ejection fraction) and quality of life attributes, a 
phenomenom confirmed in this study (78). Rather, symptomatic improvement is 
generally believed to be primarily determined by alterations in peripheral 
hemodynamics and blood distribution (79). In the present study, the addition of 
felodipine to a daily medical regimen including enalapril yielded no significant 
amelioration of symptoms or improvement in functional abilities from those present at 
baseline. Perhaps a relative localization of pharmacologic action to the coronary 
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vascular bed provides an explanation for why felodipine therapy did not improve either 
functional or symptomatic status over placebo in this group of CHF patients already on 
stable doses of a peripheral vasodilator. 
G. Tolerance & Side Effect Profile 
Felodipine was well tolerated by those subjects randomized to receive the active 
drug in a daily dose range of 5.0-10.0 mg. Only one individual reported worsening 
pedal edema unassociated with other signs of worsening heart failure, a common 
though not yet well understood side effect of the dihydropyridine calcium channel 
antagonists. No subjects complained of palpitations, lightheadedness, increased 
dyspnea, or anginal discomfort; nor were any subjects found to suffer from reflex 
tachycardia, profound hypotension, new ischemic changes on electrocardiogram, or 
worsened rales on serial physical examinations. As opposed to previous studies with 
other calcium entry blockers, there were no significant rises in serum creatinine levels 
or declines in either left ventricular ejection fractions or exercise tolerance time. Indeed, 
if anything all subjects receiving felodipine were partially relieved from their heart 
failure symptoms and improved clinically. 
No subjects receiving placebo suffered an adverse effect from medication. 
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12. CONCLUSIONS 
Based upon careful review of the data, the following conclusions may be drawn: 
1. Subacute, reversible myocardial ischemia is seen in high prevalence among 
patients with a history of coronary artery disease and limited by CHF; 
2. Both clinically and electrocardiographically silent myocardial ischemia was 
demonstrated in 58% of subjects having scintigraphic evidence for reversible 
myocardial ischemia; 
3. Felodipine's anti-ischemic properties allow for significant reduction in the 
normalized area of active myocardial ischemia in subjects with initial thallium 
scans revealing greater than 10% reversible perfusion defects; 
4. Significant reductions in both mean systolic blood presure and diastolic blood 
pressure were observed among subjects receiving eight weeks of felodipine 
therapy versus placebo; 
5. Felodipine, which offers vascular selectivity without negative Inotropic 
properties, can be safely administered to CHF patients with ischemic 
cardiomyopathy in a dose range of 5.0-10.0 mg/day divided into a BID 
regimen; 
6. No clear cut clinical benefit in terms of either exercise tolerance, functional 
status, or quality of life assessment was demonstrated by the addition of 
felodipine to this group of CHF patients; 
7. Future studies documenting the clinical efficacy of felodipine in coronary 
patients limited by symptoms of CHF and having scintigraphic evidence of 
greater than 10% reversible myocardial ischemia are warranted. 
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